Financhill
Sell
32

LNTH Quote, Financials, Valuation and Earnings

Last price:
$77.70
Seasonality move :
35.07%
Day range:
$74.41 - $77.61
52-week range:
$73.11 - $126.89
Dividend yield:
0%
P/E ratio:
21.91x
P/S ratio:
3.61x
P/B ratio:
4.58x
Volume:
1.1M
Avg. volume:
1.3M
1-year change:
-5.74%
Market cap:
$5.3B
Revenue:
$1.5B
EPS (TTM):
$3.52

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
LNTH
Lantheus Holdings
$379.1M $1.65 -1.12% 91.29% $129.31
CATX
Perspective Therapeutics
$143.9K -$0.27 -- -55.87% $13.8214
ELMD
Electromed
$15.8M -- 12.26% -- $37.00
HOLX
Hologic
$1B $1.02 -0.54% 28.19% $67.14
VNRX
VolitionRX
$1.1M -$0.05 6.24% -40.63% $2.93
XTNT
Xtant Medical Holdings
$31.2M -$0.01 4.73% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
LNTH
Lantheus Holdings
$77.13 $129.31 $5.3B 21.91x $0.00 0% 3.61x
CATX
Perspective Therapeutics
$2.3900 $13.8214 $177.4M -- $0.00 0% 16.84x
ELMD
Electromed
$20.46 $37.00 $171.6M 25.90x $0.00 0% 2.99x
HOLX
Hologic
$62.01 $67.14 $13.8B 26.16x $0.00 0% 3.58x
VNRX
VolitionRX
$0.53 $2.93 $54.4M -- $0.00 0% 36.37x
XTNT
Xtant Medical Holdings
$0.66 $1.75 $92.1M -- $0.00 0% 0.74x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
LNTH
Lantheus Holdings
32.75% -2.018 8.4% 5.19x
CATX
Perspective Therapeutics
-- -0.117 -- --
ELMD
Electromed
-- 2.256 -- 4.79x
HOLX
Hologic
35.28% 0.914 18.29% 2.29x
VNRX
VolitionRX
-29.91% 1.866 11.38% 0.34x
XTNT
Xtant Medical Holdings
43.24% 1.041 51.14% 0.96x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
LNTH
Lantheus Holdings
$237.7M $106.8M 15.45% 23.53% 27.18% $98.8M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
ELMD
Electromed
$12.2M $2.1M 16.57% 16.57% 13.65% $2.2M
HOLX
Hologic
$377.3M $37.9M 7.53% 11.45% 0.06% $129.2M
VNRX
VolitionRX
-- -$5.4M -- -- -2183.56% -$4.3M
XTNT
Xtant Medical Holdings
$20.2M $1.1M -15.44% -26.62% 3.28% $87K

Lantheus Holdings vs. Competitors

  • Which has Higher Returns LNTH or CATX?

    Perspective Therapeutics has a net margin of 19.57% compared to Lantheus Holdings's net margin of --. Lantheus Holdings's return on equity of 23.53% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    LNTH
    Lantheus Holdings
    63.77% $1.02 $1.7B
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About LNTH or CATX?

    Lantheus Holdings has a consensus price target of $129.31, signalling upside risk potential of 67.65%. On the other hand Perspective Therapeutics has an analysts' consensus of $13.8214 which suggests that it could grow by 478.3%. Given that Perspective Therapeutics has higher upside potential than Lantheus Holdings, analysts believe Perspective Therapeutics is more attractive than Lantheus Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    LNTH
    Lantheus Holdings
    9 1 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is LNTH or CATX More Risky?

    Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.093, suggesting its more volatile than the S&P 500 by 9.29%.

  • Which is a Better Dividend Stock LNTH or CATX?

    Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LNTH or CATX?

    Lantheus Holdings quarterly revenues are $372.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Lantheus Holdings's net income of $72.9M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Lantheus Holdings's price-to-earnings ratio is 21.91x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.61x versus 16.84x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LNTH
    Lantheus Holdings
    3.61x 21.91x $372.8M $72.9M
    CATX
    Perspective Therapeutics
    16.84x -- -- -$18.2M
  • Which has Higher Returns LNTH or ELMD?

    Electromed has a net margin of 19.57% compared to Lantheus Holdings's net margin of 12.06%. Lantheus Holdings's return on equity of 23.53% beat Electromed's return on equity of 16.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    LNTH
    Lantheus Holdings
    63.77% $1.02 $1.7B
    ELMD
    Electromed
    77.97% $0.21 $43.9M
  • What do Analysts Say About LNTH or ELMD?

    Lantheus Holdings has a consensus price target of $129.31, signalling upside risk potential of 67.65%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 80.84%. Given that Electromed has higher upside potential than Lantheus Holdings, analysts believe Electromed is more attractive than Lantheus Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    LNTH
    Lantheus Holdings
    9 1 0
    ELMD
    Electromed
    2 0 0
  • Is LNTH or ELMD More Risky?

    Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

  • Which is a Better Dividend Stock LNTH or ELMD?

    Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LNTH or ELMD?

    Lantheus Holdings quarterly revenues are $372.8M, which are larger than Electromed quarterly revenues of $15.7M. Lantheus Holdings's net income of $72.9M is higher than Electromed's net income of $1.9M. Notably, Lantheus Holdings's price-to-earnings ratio is 21.91x while Electromed's PE ratio is 25.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.61x versus 2.99x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LNTH
    Lantheus Holdings
    3.61x 21.91x $372.8M $72.9M
    ELMD
    Electromed
    2.99x 25.90x $15.7M $1.9M
  • Which has Higher Returns LNTH or HOLX?

    Hologic has a net margin of 19.57% compared to Lantheus Holdings's net margin of -1.73%. Lantheus Holdings's return on equity of 23.53% beat Hologic's return on equity of 11.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    LNTH
    Lantheus Holdings
    63.77% $1.02 $1.7B
    HOLX
    Hologic
    37.53% -$0.08 $7.1B
  • What do Analysts Say About LNTH or HOLX?

    Lantheus Holdings has a consensus price target of $129.31, signalling upside risk potential of 67.65%. On the other hand Hologic has an analysts' consensus of $67.14 which suggests that it could grow by 8.28%. Given that Lantheus Holdings has higher upside potential than Hologic, analysts believe Lantheus Holdings is more attractive than Hologic.

    Company Buy Ratings Hold Ratings Sell Ratings
    LNTH
    Lantheus Holdings
    9 1 0
    HOLX
    Hologic
    3 13 0
  • Is LNTH or HOLX More Risky?

    Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Hologic has a beta of 0.549, suggesting its less volatile than the S&P 500 by 45.069%.

  • Which is a Better Dividend Stock LNTH or HOLX?

    Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LNTH or HOLX?

    Lantheus Holdings quarterly revenues are $372.8M, which are smaller than Hologic quarterly revenues of $1B. Lantheus Holdings's net income of $72.9M is higher than Hologic's net income of -$17.4M. Notably, Lantheus Holdings's price-to-earnings ratio is 21.91x while Hologic's PE ratio is 26.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.61x versus 3.58x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LNTH
    Lantheus Holdings
    3.61x 21.91x $372.8M $72.9M
    HOLX
    Hologic
    3.58x 26.16x $1B -$17.4M
  • Which has Higher Returns LNTH or VNRX?

    VolitionRX has a net margin of 19.57% compared to Lantheus Holdings's net margin of -2201.34%. Lantheus Holdings's return on equity of 23.53% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    LNTH
    Lantheus Holdings
    63.77% $1.02 $1.7B
    VNRX
    VolitionRX
    -- -$0.06 -$22.6M
  • What do Analysts Say About LNTH or VNRX?

    Lantheus Holdings has a consensus price target of $129.31, signalling upside risk potential of 67.65%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 454.86%. Given that VolitionRX has higher upside potential than Lantheus Holdings, analysts believe VolitionRX is more attractive than Lantheus Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    LNTH
    Lantheus Holdings
    9 1 0
    VNRX
    VolitionRX
    2 1 0
  • Is LNTH or VNRX More Risky?

    Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.247%.

  • Which is a Better Dividend Stock LNTH or VNRX?

    Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LNTH or VNRX?

    Lantheus Holdings quarterly revenues are $372.8M, which are larger than VolitionRX quarterly revenues of $246.4K. Lantheus Holdings's net income of $72.9M is higher than VolitionRX's net income of -$5.4M. Notably, Lantheus Holdings's price-to-earnings ratio is 21.91x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.61x versus 36.37x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LNTH
    Lantheus Holdings
    3.61x 21.91x $372.8M $72.9M
    VNRX
    VolitionRX
    36.37x -- $246.4K -$5.4M
  • Which has Higher Returns LNTH or XTNT?

    Xtant Medical Holdings has a net margin of 19.57% compared to Lantheus Holdings's net margin of 0.18%. Lantheus Holdings's return on equity of 23.53% beat Xtant Medical Holdings's return on equity of -26.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    LNTH
    Lantheus Holdings
    63.77% $1.02 $1.7B
    XTNT
    Xtant Medical Holdings
    61.52% -- $77.3M
  • What do Analysts Say About LNTH or XTNT?

    Lantheus Holdings has a consensus price target of $129.31, signalling upside risk potential of 67.65%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 164.79%. Given that Xtant Medical Holdings has higher upside potential than Lantheus Holdings, analysts believe Xtant Medical Holdings is more attractive than Lantheus Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    LNTH
    Lantheus Holdings
    9 1 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is LNTH or XTNT More Risky?

    Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

  • Which is a Better Dividend Stock LNTH or XTNT?

    Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LNTH or XTNT?

    Lantheus Holdings quarterly revenues are $372.8M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. Lantheus Holdings's net income of $72.9M is higher than Xtant Medical Holdings's net income of $58K. Notably, Lantheus Holdings's price-to-earnings ratio is 21.91x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.61x versus 0.74x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LNTH
    Lantheus Holdings
    3.61x 21.91x $372.8M $72.9M
    XTNT
    Xtant Medical Holdings
    0.74x -- $32.9M $58K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is IONQ The Next NVIDIA?
Is IONQ The Next NVIDIA?

Quantum computing startup IonQ (NYSE:IONQ) has seen its stock skyrocket…

Best AI Index Fund to Buy
Best AI Index Fund to Buy

Over the last two years, companies with a focus on…

Where Will Salesforce Stock Be in 5 Years?
Where Will Salesforce Stock Be in 5 Years?

Salesforce (NYSE: CRM) just turned in a quarter that, on…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 47x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
VERA alert for Jun 3

Vera Therapeutics [VERA] is down 2.55% over the past day.

Buy
80
KYMR alert for Jun 3

Kymera Therapeutics [KYMR] is up 1.21% over the past day.

Buy
78
SBET alert for Jun 3

SharpLink Gaming [SBET] is down 8.56% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock